MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pulmonary Hypertension
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 40 years and 80 years
- Gender
- Both males and females
Description
Part 1 of this study will assess safety, tolerability, and PK of MK-5475 compared to placebo. Part 2 of this study will assess safety, tolerability, PK, and changes in PVR and PBV of MK-5475 compared to placebo.
Part 1 of this study will assess safety, tolerability, and PK of MK-5475 compared to placebo. Part 2 of this study will assess safety, tolerability, PK, and changes in PVR and PBV of MK-5475 compared to placebo.
Tracking Information
- NCT #
- NCT04370873
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Merck Sharp & Dohme Corp.
Get Well Soon